Can-Fite BioPharma Ltd. (CANF)
AMEX: CANF
· Real-Time Price · USD
0.63
0.02 (3.26%)
At close: Sep 26, 2025, 3:59 PM
0.63
0.00%
After-hours: Sep 26, 2025, 03:59 PM EDT
3.26% (1D)
Bid | 0.61 |
Market Cap | 5.48M |
Revenue (ttm) | 674K |
Net Income (ttm) | -7.88M |
EPS (ttm) | -2.6 |
PE Ratio (ttm) | -0.24 |
Forward PE | -15.47 |
Analyst | Buy |
Dividends | n/a |
Ask | 0.64 |
Volume | 73,816 |
Avg. Volume (20D) | 200,820 |
Open | 0.62 |
Previous Close | 0.61 |
Day's Range | 0.61 - 0.63 |
52-Week Range | 0.60 - 3.12 |
Beta | 0.09 |
Ex-Dividend Date | n/a |
About CANF
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CANF
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CANF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-28.43%
Can-Fite Biopharma shares are trading lower after ...
Unlock content with
Pro Subscription
6 months ago
-19.31%
Can-Fite Biopharma shares are trading lower. The company announced a Phase II design is completed and preparatory work is undergoing for the initiation of clinical study in the rare genetic disease Lowe Syndrome.